CHIMIX CELL THERAPY
DEAD

Serial Number

97806112

Owner

Medeor Acquisition Corp.

Attorney

Britt L. Anderson

Filing Date

Feb 22, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CHIMIX CELL THERAPY Trademark

Serial Number: 97806112

CHIMIX CELL THERAPY is a trademark filed by Medeor Acquisition Corp. on February 22, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Medeor Acquisition Corp. (2 trademarks)

611 Gateway Blvd., Suite 120
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

February 22, 2023

Registration Date

Not Registered

Published for Opposition

January 2, 2024

Goods & Services

Blood and bone marrow for medical purposes, namely, processed blood and bone marrow for preventing and treating rejection of transplanted kidneys, transplanted livers, transplanted hearts, and other transplanted organs; Blood and bone marrow for medical purposes, namely, processed blood and bone marrow for control and suppression of the immune system; Blood and bone marrow for medical purposes, namely, processed blood and bone marrow for induction of immune tolerance; Blood and bone marrow for medical purposes, namely, processed blood and bone marrow for treating and destroying cancer cells

Medical services, namely, processing blood and bone marrow to prevent and treat rejection of transplanted kidneys, transplanted livers, transplanted hearts, and other transplanted organs; Medical services, namely, processing blood and bone marrow for control and suppression of the immune system; Medical services, namely, processing blood and bone marrow for immune destruction of cancer cells; Medical services in the field of preventing and treating rejection of transplanted kidneys, transplanted livers, transplanted hearts, and other transplanted organs; Medical services in the field of control and suppression of the immune system; Medical services in the field of induction of immune tolerance; Medical services in the field of treating and destroying cancer cells; Medical testing for diagnostic or treatment purposes in the field of preventing and treating rejection of transplanted kidneys, transplanted livers, transplanted hearts, and other transplanted organs; Medical testing for diagnostic or treatment purposes in the field of control and suppression of the immune system blood analysis services

Clinical research in the field of human diseases; research and development services in the field of immunology and hematology; scientific, medical, and biological research; research and development in the field of pharmaceutical products

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 30, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 30, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 27, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 2, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 2, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 13, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 22, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 22, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 22, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 22, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 22, 2023 CNEA
ASSIGNED TO EXAMINER
Nov 21, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 13, 2023 NWOS
NEW APPLICATION ENTERED
Feb 25, 2023 NWAP